Pharmacokinetic method developed for pan-RAS inhibitor

▸ TREATMENT

Researchers validated a mass spectrometry assay to measure daraxonrasib, an oral pan-RAS inhibitor in clinical evaluation for colorectal cancer, in canine plasma and whole blood, supporting pharmacokinetic characterization of the investigational drug. (Biomed Chromatogr)